罗格列酮钠联合二甲双胍改善2型糖尿病患者糖脂代谢及机制研究

目的探讨罗格列酮钠联合二甲双胍治疗对2型糖尿病患者糖脂代谢及胰岛素抵抗改变及其作用机制。方法 42例确诊2型糖尿病患者经过二甲双胍及罗格列酮钠干预治疗12周。检测治疗前后空腹血糖(FBS)、餐后2h血糖(PBS)、空腹胰岛素(FINS)、血清总胆固醇(TC)、三酰甘油(TG)低密度胆固醇(LDL)等血脂全套,用HOMA公式计算胰岛素抵抗指数(IR)与正常对照组34例相比较。同时测定治疗前后血清游离脂肪酸(FFA)、C反应蛋白(CRP)。结果 2型糖尿病患者与对照组比,FBS、PBS、HbA1c、LDL、TC、TG、FFA、CRP、IR均显著增高。2型糖尿病组经干预治疗后,FBS、PBS、HbA1c、IR、FFA、CRP浓度均比治疗前显著下降(P<0.01)。LDL、TC、TG经治疗后亦有明显下降(P<0.01)。结论罗格列酮钠联合二甲双胍治疗肥胖2型糖尿病患者可通过降低CRP、FFA,改善IR从而改善糖脂代谢。

Combined treatment of Rosiglitazone and Metformin improved Glycolipid Metabolism of Type 2 Diabetic Mellitus Patients and Its Mechanism Study

Objective To approach the effects of metformin combined rosiglitazone sodium on the glycolipid metabolism and insulin resistance of type 2 diabetic mellitus patients and its mechanism.Methods 42 determined type 2 diabetic mellitus patients were received metformin and rosiglitazone sodium for 12 weeks.Fasting blood sugar（FBS）,postprandial blood sugar（PBS）,fasting insulin and blood lipid ect were measured before and after the treatment,Homeostasis Model Assessment for insulin resistance[HOMA（IR）],compared with the normal.Besides,free fatty acids（FFA） and C reactive protein（CRP） were also measured before and after the treatment.Results Compared with the normal,FBS,PBS,HbA1c,LDL,TC,TG,FFA,CRP,IR were notablely increased in type 2 diabetic patients.Compared with pret＇reatment data,FBS,PBS,HbA1c,IR,FFA,CRP levels after treatment notablely decreased in type 2 diabetic patients（P0.01）,LDL,TC,TG also decreased（P0.01）.Conclusion Combination of rosiglitazone sodium and metformin significantly decreased CRP,FFA,improved insulin resistance and then improved glycolipid metabolism.